Sign in
Taking peopleNo phase

Testing the marker miR371 in testicular germ cell cancer

Studies how well miR371 tracks disease in testicular cancer.

Key facts

Who runs it
Haukeland University Hospital
Where
Norway and Sweden6 sites in 2 countriesChoose a country to see its sites
Trial code
Registry title
MicroRNA as Markers in Testicular Cancer
Status
Recruiting
People taking part
350 people, planned
Started
31 Dec 2016
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Biomarker analysis
Record updated
8 August 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with suspected or diagnosed testicular germ cell cancer. It tests a blood marker, miR371, to follow the disease.

Age
18 to 70 years
Sex
Men only
Disease stage
Suspected testicular cancer referred for surgery to remove the testicle (orchiectomy), or diagnosed testicular germ cell cancer. Conditions listed include stage I to IV and relapsed disease.

Main reasons for not taking part

  • Another cancer now or in the past, other than testicular cancer
  • Other diseases or conditions that make it hard to receive information and take part in follow-up
  • Not able to receive information and give consent

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with suspected testicular cancer, referred to orchiectomy
  • Patients diagnosed with testicular germ cell cancer
  • Age 18-70 years of age
  • Must be able receive information and to consent

Who cannot take part

  • Other prior or concomitant malignancy (other than testicular cancer)
  • Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Treatments tested

  • Biomarker analysis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
Plain-language title
Testing the marker miR371 in testicular germ cell cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT04914026, who can take part
Record updated
8 August 2022